Biobetter spotted what looks to be 2 more cabo late breakers. I'm a little surprised that CRADA hasn't developed a Colon cancer study, but I guess we have some preclinical work on that indication.
Presentation Title: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of cabozantinib
Author Block: Malcolm Smith, Min Kang, Patrick Reynolds, Richard Gorlick, Anders Kolb, John Maris, Stephen Keir, Catherine Billups, Raushan Kurmasheva, Peter Houghton. National Cancer Institute, Bethesda, MD, Texas Tech University Health Sciences Center, Lubbock, TX, Montefiore Medical Center, Bronx, NY, A.I. duPont Hospital for Children, Wilmington, DE, Children’s Hospital Philadelphia, Philadelphia, PA, Duke University Medical Center, Durham, NC, St. Jude Children’s Research Hospital, Memphis, TN, Nationwide Children's Hosp. Ctr. for Childhood Cancer, Columbus, OH
Potent antitumor activity of XL184 (cabozantinib), a c-MET and VEGFR2 inhibitor, in colorectal cancer patient-derived tumor explant models
Author Block: Chloe E. Atreya, Eun-Kee Song, Wells Messersmith, Alicia Purkey, Stacey Bagby, Kevin Quackenbush, Robin K. Kelley, Eunice Kwak, David Ryan, Alan Venook, John J. Arcaroli. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Univ. of Colorado Denver, Aurora, CO, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Abstract Number: LB-166
Presentation Title: Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study.
Location: Hall A-C, Poster Section 47
Author Block: Christopher J. Sweeney, Katherine Zukotynski, Xiaodong Wang, Andrew Wick, Amanda Fredericks, Bon Lam, Philip Kantoff. Dana Farber Cancer Inst., Boston, MA
Nice find! Ultimately they'll want to try Enzalutamide + Abiraterone + low dose Cabo in early stage prostate cancer to block off as many known signaling escape paths as possible, with an escalation in Cabo if the cancer becomes more Androgen independent. I imagine Sipuleucel-T would also stack on top of that, but the cost of so many lines of therapy would only be available to the rich.